Viral load

Resource
February 21, 2019
Depression is a leading cause of disability and may be associated with decreased adherence to ART. We sought to describe the prevalence of depressive symptoms and outcomes one year after screening among patients receiving ART at a large HIV Clinic in Johannesburg, South Africa.
Resource
February 5, 2019

The amount of HIV in your body fluids is called your viral load. Effective HIV treatment (antiretroviral therapy) suppresses the amount of HIV in your body fluids to the point where standard tests are unable to detect any HIV, or can only find a tiny trace. Doctors call this ‘virological suppress

Resource
January 29, 2019

Across sub-Saharan Africa, prevention of mother-to-child transmission services are encountering increasing numbers of women already established on antiretroviral therapy (ART) when entering antenatal care.

Resource
January 22, 2019
Initiation of antiretroviral therapy (ART) following diagnosis of HIV infection at birth is an emerging area of paediatric HIV care. We present outcomes of HIV-infected infants identified at birth at Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa.
News
January 15, 2019

The efficacy of first-line antiretroviral therapy (ART) continues to improve, according to an analysis of outcomes in 78,000 people in 181 studies, published in AIDS by Professor Andrew Carr of St Vincent's Hospital in Sydney and colleagues.

News
January 14, 2019

In recent years, an overwhelming body of clinical evidence has firmly established the HIV Undetectable = Untransmittable (U=U) concept as scientifically sound, say officials from the National Institutes of Health.

Resource
January 14, 2019

In 2016, the Prevention Access Campaign, a health equity initiative with the goal of ending the HIV/AIDS pandemic as well as HIV-related stigma, launched the Undetectable = Untransmittable (U = U) initiative. U = U signifies that individuals with HIV who receive antiretroviral therapy (ART) and h

News
January 8, 2019

Multiple partners, migration, and living in an HIV ‘hotspot’ have been identified as key drivers of unsuppressed viral load among young women living with HIV in KwaZulu-Natal, South Africa.

Event
November 14, 2018

Known as the “African CROI” the INTEREST Conference brings together scientists involved in HIV treatment, pathogenesis, and prevention research in Africa to share pivotal findings, promote collaboration, and transfer experiences across several fields and many continents.

Resource
October 26, 2018
Since 2016, WHO has recommended tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) (or emtricitabine, FTC) + efavirenz (EFV) 600 mg as the preferred first- line antiretroviral therapy (ART) regimen for adults and adolescents. WHO recommended dolutegravir (DTG) as an alternative option to EFV for first-line ART because of the uncertainty regarding the safety and efficacy of DTG during pregnancy and among people living with HIV receiving rifampicin-based tuberculosis (TB) treatment. New WHO interim guidelines contain recommendations regarding preferred first-line regimens for adults, adolescents and children initiating ART, which now include DTG and RAL.